Wechselwirkungen · Hemgenix
Hemgenix 1 x 1013 genome copies/mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 10
HOS-142204 · Präparat HOS-098776
Before administering etranacogene dezaparvovec to patients receiving potentially hepatotoxic medicinal products or using other hepatotoxic agents (including alcohol, potentially hepatotoxic herbal products and nutritional supplements) and when deciding on the acceptability of such agents after treatment with etranacogene dezaparvovec, physicians should consider that they may reduce the efficacy of etranacogene dezaparvovec and increase the risk for more serious hepatic reactions, particularly during the first year following etranacogene dezaparvovec administration (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-27T17:00:00Z · SHA-256 401706c55058fc08bee543581a5958c55aedec3e84eb254d503c8ac238757ce2 · Passage 3b24c7f8c18c37623fbd2a3ccf1666e364f6c8f8e35bf3164f1c4d03097c8a87 · Zeichen 1031–1620 im Abschnitt